Omeros Reports Strong Q1 Profitability Driven by Initial YARTEMLEA Sales and Debt Reduction

summarizeSummary

Omeros Corporation reported a significant return to profitability in Q1 2026, driven by the first commercial sales of its newly approved drug YARTEMLEA and a stronger balance sheet following recent debt repayments.

check_boxKey Events

• Return to Profitability

  Achieved net income of $56.1 million in Q1 2026, a substantial improvement from a $33.5 million net loss in the prior year period.

• Initial YARTEMLEA Sales

  Generated $9.9 million in net product sales from YARTEMLEA, its newly approved drug for TA-TMA, marking its first commercial quarter.

• Strengthened Balance Sheet

  Repaid $17.1 million of 2026 Notes upon maturity and previously repaid a $67.1 million Term Loan, leaving only $70.8 million in 2029 Notes outstanding.

• Share Repurchase Program Active

  Repurchased $4.2 million of common stock during the quarter, with $95.9 million remaining under the authorized program.

auto_awesomeAnalysis

This quarterly report provides the first financial results reflecting the commercial launch of YARTEMLEA and the impact of the Zaltenibart asset sale. The significant swing to profitability, driven by initial product sales and a substantial non-cash gain from derivative remeasurement, coupled with reduced debt, marks a strong improvement in Omeros' financial health. The active share repurchase program further indicates management's confidence. The company's improved liquidity position, with over 12 months of operational funding, reduces immediate financial concerns.